Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2009 Apr 21;18(5):1448–1456. doi: 10.1158/1055-9965.EPI-08-0936

Table 1.

Sociodemographic characteristics and estrogen exposure related variables for cases and controls

Cases n (%) Controls n (%) Age adjusted OR (95%CI)
Age
 <55 103 (22) 85 (18)
 55–64 205 (44) 159 (34)
 65–74 108 (23) 127 (27)
 ≥75 53 (11) 96 (21)
Race
 White 399(85) 408(87) 1 (ref)
 Black 38(8) 23(5) 1.6 (1.0 – 2.8)
 Hispanic 23(5) 23(5) 0.9 (0.5 – 1.7)
 Other 9(2) 13(3) 0.6 (0.3 – 1.4)
Educational level
 High school 169(36) 155(33) 1 (ref)
 College 207(44) 193(41) 0.9 (0.7 – 1.2)
 Graduate school 93(20) 119(26) 0.6 (0.5 – 0.9)
Smoking
 Never 263(56) 238(51) 1 (ref)
 Former 173(37) 178(38) 0.9 (0.7 – 1.2)
 Current 33(7) 51(11) 0.5 (0.3 – 0.8)
BMI
 <25 118(25) 212(45) 1 (ref)
 25–<30 127(27) 152(33) 1.6 (1.1 – 2.2)
 30–<35 80(17) 71(15) 2.0 (1.4 – 3.0)
 ≥35 142(30) 32(7) 7.6 (4.8 – 11.8)
Early menarche (<12 years)
 No 202(43) 232(50) 1 (ref)
 Yes 267(57) 235(50) 1.2 (1.0 – 1.6)
Parity
 0–1 171(37) 114(24) 1 (ref)
 2 157(34) 167(36) 0.6 (0.5 – 0.9)
 ≥3 141(30) 186(40) 0.6 (0.4 – 0.8)
Menopausal status at index date
 Premenopausal 78(17) 66(14) 0.9 (0.6 –1.5)
 Early menopause (<50) 122(26) 142(30) 1 (ref)
 Late menopause(≥50) 216(46) 199(43) 1.3 (1.0 – 1.8)
 Post menopause, age unknown 53(11) 59(13) 1.1 (0.7 – 1.7)
Oral contraceptive use
 No 268(57) 241(52) 1 (ref)
 Yes 201(43) 226(48) 0.7 (0.5 – 0.9)
Hormone replacement therapy use
 Never 376(80) 345(74) 1 (ref)
 Unopposed estrogen replacement therapy only 37(8) 39(8) 0.9 (0.5 – 1.4)
 Ever combined replacement therapy 56(12) 83(18) 0.6 (0.4 – 0.8)
Family history of endometrial cancer
 No 444(95) 451(97) 1 (ref)
 Yes 25(5) 16(3) 1.6 (0.9 – 3.1)